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Abstract
Background: Cancer-initiating cell (CIC) exosomes (CIC-TEX) are suggested reprogramming Non-CIC. Mode of
message transfer and engagement of CIC-markers being disputed, we elaborated the impact of CD44v6 and
Tspan8 on the response of Non-CIC.
Methods: Non-metastasizing CD44v6- and Tspan8-knockdown (kd) pancreatic cancer cells served as Non-CIC.
CIC-TEX coculture-induced changes were evaluated by deep-sequencing and functional assays. Tumor progression
was surveyed during in vivo CIC-TEX treatment.
Results: Deep-sequencing of CIC-TEX-cocultured CD44v6kd-Non-CIC revealed pronounced mRNA changes in
signaling, transport, transcription and translation; altered miRNA affected metabolism, signaling and transcription.
CIC-TEX coculture-induced changes in Tspan8kd-Non-CIC mostly relied on CIC-TEX-Tspan8 being required for
targeting. CIC-TEX transfer supported apoptosis resistance and significantly promoted epithelial mesenchymal
transition, migration, invasion and (lymph)angiogenesis of the kd Non-CIC in vitro and in vivo, deep-sequencing
allowing individual mRNA and miRNA assignment to altered functions. Importantly, CIC-TEX act as a hub, initiated
by CD44v6-dependent RTK, GPCR and integrin activation and involving CD44v6-assisted transcription and RNA
processing. Accordingly, a kinase inhibitor hampered CIC-TEX-fostered tumor progression, which was backed by an
anti-Tspan8 blockade of CIC-TEX binding.
Conclusions: This in depth report on the in vitro and in vivo impact of CIC-TEX on CD44v6kd and Tspan8kd Non-
CIC unravels hub CIC-TEX activity, highlighting a prominent contribution of the CIC-markers CD44v6 to signaling
cascade activation, transcription, translation and miRNA processing in Non-CIC and of Tspan8 to CIC-TEX targeting.
Blocking CIC-TEX binding/uptake and uptake-initiated target cell activation significantly mitigated the deleterious
CIC-TEX impact on CD44v6kd and Tspan8kd Non-CIC.
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Background
Pancreatic cancer (PaCa) has the highest cancer mortality
rate and incidence is increasing [1]. High mortality, due to
early spread and radio- and chemotherapy-resistance [2],
is provoked by a small population of cancer-initiating cells
(CIC) [3], which mainly act via exosomes (CIC-TEX) [4].
Exosomes (Exo), a subpopulation of small extracellular
vesicles [5] are delivered by live cells [6]. They are com-
posed of a lipid bilayer, integrated and membrane-attached
proteins, some, prominently tetraspanins being engaged in
Exo-biogenesis and -targeting [7]. The Exo plasma contains
non-randomly recruited proteins, coating and non-coating
RNA and DNA [6–9]. Exo components are function com-
petent, message delivery severely affecting targets [10].
CIC-TEX reorganize the tumor stroma, stimulate angio-
genesis, promote deviation of hematopoiesis towards im-
munosuppressive cells and transiently reprogram Non-CIC
towards anchorage-independence, apoptosis-resistance,
motility and invasion [11–14]. We focused on the
CIC-TEX impact on Non-CIC, selecting cells with a knock-
down (kd) of the PaCIC biomarkers CD44v6 (v6) and
Tspan8 (Tsp8) as Non-CIC.
CD44v6 CIC-biomarker activity in PaCa [15] relies
on the association with receptor tyrosine kinases
(RTK), the engagement in Wnt signaling by associating
with LPR6 (LDL receptor related protein 6)1 (see also
Additional file 1: Table S1) and a contribution to
NOTCH and Nanog epithelial-mesenchymal transition
(EMT)-transcription factor activation [16–18]. CD44v6
also supports apoptosis-resistance, mostly via drug efflux,
and facilitates tumor cell motility by protease transcription
activation and protease proform cleavage promoting
matrix remodeling [19, 20]. Regulation of miRNA process-
ing adds to v6 CIC-biomarker activity [21, 22].
Metastasis-promoting Tsp8 [23] associations with integ-
rins facilitates motile phenotype acquisition; protease links
support path-creation for migrating tumor cells [24, 25].
The tetraspanin engagement in Exo-biogenesis and target-
ing is fundamental for the TEX-target crosstalk [26]. Tet-
raspanins connect with a multitude of transmembrane
and cytosolic molecules in glycolipid-enriched membrane
domains (TEM) [27]. TEM complexes, prone for internal-
ization, are maintained during Exo biogenesis, TEX-Tsp8
most weightily forcing targeting [27–30].
Finally, there are two links between Tsp8 and v6.
CD44v6 is Tsp8-associated in TEM and v6 promotes
Tsp8 transcription [31, 32].
A v6kd and a Tsp8kd severely affecting PaCa progres-
sion [32–34], we aimed elaborating the molecular mech-
anism of v6 and Tsp8 in CIC-TEX activity. To achieve
this goal, deep-sequencing (DS) was performed of
CIC-TEX, untreated and CIC-TEX-treated v6kd and
Tsp8kd cells. Correlating DS results with protein recov-
ery and functional in vitro and in vivo studies uncovered
v6 being central in CIC-TEX shaping. CIC-TEX, acting
as hub initiating Non-CIC activation, profit from mes-
sage delivery by Tsp8.
Methods
Tumor lines
The human PaCa lines A818.4 [35], Capan-1 [36], −v6kd
and -Tsp8kd cells [32] and pcDNA3EGFP-Neomycin ex-
pression vector (Addgene) transfected A818.4 (A818.4-
GFP < green fluorescence protein>) were maintained in
RPMI1640/10%FCS/pyruvate/L-glutamine/antibiotics,
transfected lines containing 0 .5mg/ml G418.
Antibodies and reagents
Additional file 1: Table S2A, S2B.
CIC-enrichment
Capan1-CIC were enriched by spheroid growth;
A818.4-CIC by holoclone formation [32]. After 3 rounds
of cloning, spheres/holoclones were cultured for 48 h in
FCS-free medium. After 24 h recovery (medium with 10%
Exo-depleted FCS), TEX were collected for an additional
48 h in FCS-free medium. Thereafter CIC-enriched cells
were discarded.
Tissue preparation
Nude mice were sacrificed by cervical dislocation or
were anesthetized (CO2) collecting peripheral blood /
peripheral blood leukocytes (PB, PBL) by heart puncture
(100 U heparin/syringe). Tumors, liver, lung and
hematopoietic / lymphoid tissues (bone marrow cells
<BMC>, lymph node(s)/ <LN, LNC>, peritoneal exudate
cells <PEC>, spleen cells <SpC>) were excised, shock
frozen or dispersed.
TEX preparation
Tumor cell supernatants were cleared (2x10min, 500 g,
1x20min, 2000 g, 1x30min, 10,000 g, 4 °C), filtered
(0.22 μm) and centrifuged (120 min, 100,000 g, 4 °C).
After washing (PBS, 120 min, 100,000 g, 4 °C), the pellet
was resuspended in 40% sucrose overlaid by a discon-
tinuous sucrose gradient (30–5%) and centrifuged (16 h,
100,000 g, 4 °C) collecting TEX from the 10–5% sucrose
interface (light density fractions, d: 1.15–1. 56 g/ml) [28].
Protein concentrations were determined by Bradford.
Where indicated, TEX were labeled with SP-DioC18(3)
(3,3′-dioctadecyl-5,5′-di(4-sulfophenyl)oxacarbocyanine,
Dio). After quenching (15 ml Exo-depleted FCS) and
washing (2x120min, 100,000 g), TEX were suspended in
30ml PBS layered over 10 ml 40% sucrose and
centrifuged (120 min, 100,000 g, 4 °C), collecting the
TEX-pellet at the bottom [28].
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mRNA and miRNA
Cell and TEX (RNase-pretreated) mRNA/miRNA were
extracted using miRNeasyMinikit following the sup-
plier’s suggestion (Qiagen, Hildesheim, Germany).
mRNA and miRNA deep-sequencing
mRNA and miRNA DS of cells, TEX and TEX-treated
cells were performed at the Core facility, EMBL, Heidel-
berg (ENA database accession No: PRJEB25446). Align-
ment software was STAR aligner version 2.5.2a,
reference hg19. Differential recovery was defined by
≥1.5–2-fold changes in mean signal strength of normal-
ized data.
mRNA and miRNA analysis
PANTHER (http://pantherdb.org), KEGG (http://www.
kegg.jp), Reactome (https://reactome.org), and STRING
(http://string-db.org) databases were used for mRNA
analysis. IPA (ingenuity program analysis) was used cor-
relating miRNA with mRNA expression according to
mRNA predictions (http://www.microrna.org, http://
www.targetscan.org).
Real-time PCR (qRT-PCR) and delta-Ct method ana-
lysis followed described protocols [33] using GAPDH
(mRNA) and small nuclear snRNA U6 (miRNA) as in-
ternal controls (primers: Additional file 1: Table S2C).
Western blot (WB)
Lysates (cells: 30 μg, TEX: 10 μg) (30min, 4 °C, HEPES
buffer, 1% Lubrol or 1% TritonX-100, 1mM PMSF, 1 mM
NaVO4, 10mM NaF, protease inhibitor mix) were centri-
fuged (13,000 g, 10min, 4 °C), dissolved in Laemmli buffer
and subjected to 10–12% SDS-PAGE. After protein
transfer, blocking, blotting with antibodies, blots were de-
veloped with enhanced chemiluminescence (ECL)
WB-detection-reagent. Relative signal strength in com-
parison to the actin control was evaluated by ImageJ.
Where indicated significance between distinctly treated
cell populations is indicated.
Cell cycle analysis
Starved (48 h) and recovered (2 h, RPMI/10%FCS) cells
were fixed (cold 70% ethanol, 1 h). After washing, propi-
dium iodine (PI) (50 μg/ml, 3 .8mM Na citrate) was added
(overnight, 4 °C), evaluating PI uptake by flow-cytometry.
Apoptosis-resistance
The percent apoptotic cells (AnnV-APC/PI staining)
after incubation (48 h) with cisplatin was determined by
flow-cytometry.
Flow-cytometry
TEX (10-15 μg) were coupled to 1 μl aldehyde-sulfate
latex beads (LB) (4 μm) (Invitrogen) in PBS/1% BSA (90
min, 20 °C, shaking). After centrifugation, free binding
site-blocking (100 mM glycine in PBS, 1 h) and two
washings (PBS/1%BSA), TEX-coated beads were distrib-
uted in 96-well plates. Staining with primary and sec-
ondary dye-labeled antibodies followed the protocol for
cell staining. For intracellular staining, cells/TEX were
fixed and permeabilized. Samples were analyzed in a
FACSCalibur using the CellQuest program.
Immunohistochemistry
Shock-frozen tissue sections (8 μm) were fixed, incubated
with antibodies, washed, exposed to biotinylated second-
ary antibodies and alkaline phosphatase-conjugated
avidin-biotin solution. Sections were counter-stained with
hematoxilin. Digitized images were generated using a
Leica DMRBE microscope.
Confocal microscopy
Cells were seeded on cover-slides, tissue sections on
glass-slides. Cells/tissues were fixed, permeabilized,
blocked, incubated with primary antibody, washed, incu-
bated with fluorochrome-conjugated secondary antibody
and counterstained with DAPI. Slides were mounted in
Elvanol. Digitized images were generated using a Leica
LMS800 microscope and Carl Zeiss Vision software for
evaluation.
Animal experiments
Nude mice received orthotopic (ot) or subcutaneous (sc)
tumor cell injections. When tumors (sc) reached a mean
diameter of 0 .5cm or became palpable (upper abdo-
men), tumor-bearing (TB) and control mice received an
intravenous (iv) injection of 100 μg SP-DioC18(3) labeled
TEX or GFP-transfected cell-derived TEX (TEX-GFP),
sacrificing 3 mice/group after 2 h–48 h. Where indicated,
mice received tumor injections on the left and right
upper back or received iv injections of TEX (200 μg/
100 μl NaCl, 1x or 2x/wk), or anti-Tsp8 (200 μg/100 μl
NaCl, weekly) or Gemcitabine (GEM) (100 μg/g, weekly).
Mice (5–6/group) were sacrificed tumors reaching
1 .5cm mean diameter or upon weight loss. Animal ex-
periments were Government-approved (Baden-Wuert-
temberg, Germany).
Statistics
In vitro experiments were repeated 3-times; in vivo experi-
ments 2-times. P values < 0.05 (two-tailed Student’s t-test,
Kruskal-Wallis test, where indicated after Bonferroni-Holm
correction) were considered significant and are indicated by
* or s or p-values are presented.
Results
CIC-TEX transfer CIC features into Non-CIC, the con-
tribution of CIC-biomarkers and the consequences of
Wang et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:132 Page 3 of 20
transfer being disputed. We approached the question
using A818.4 CIC-TEX and A818.4-v6kd and -Tsp8kd
cells as Non-CIC, both kd strongly impairing tumor
progression [25, 32]. In vitro assays, based on DS
analyses, were substantiated by in vivo studies of
CIC-TEX-treated TB mice.
CIC-TEX binding/uptake and metastatic growth induction
in CD44v6kd and Tspan8kd cells
Binding and uptake of CIC-TEX is a prerequisite for
Non-CIC modulation. A818.4 cells and TEX abundantly
express v6 and Tsp8 with a mutual effect of a v6kd and,
less pronounced, a Tsp8kd. A v6kd also affects MET and
a Tsp8kd CD104 expression (32). Flow-cytometry ana-
lysis validated v6 and upregulated Tsp8 recovery in TEX.
Characterization for common TEX markers confirmed
high expression of Alix, TSG101, MFG8 and tetraspa-
nins with only a minor reduction of CD63 in v6kd TEX
(Additional file 1: Figure S1a). To control for TEX up-
take in vivo, intrapancreatic TB mice received an iv
Dio-labeled TEX injection. A818.4, −v6kd and -Tsp8kd
cells take-up TEX with comparable efficacy, uptake in-
creasing until 24 h after injection. In the tumor-free pan-
creas, TEX are transiently recovered at low level. TEX
are also recovered in draining LN, BM, lung, liver, spleen
and PB (Additional file 1: Figure S1b, S1c). The
experiment was repeated with weekly iv GFP-TEX injec-
tions into sc A818.4 and -v6kd TB. Tumors and
metastasis-prone organs were excised, tumors reaching
0 .5cm mean diameter. GFP was mostly recovered in
Tsp8+ dispersed tumor tissue and draining LN
(Additional file 1: Figure S1d). Confocal microscopy of
shock-frozen tumor sections confirmed GFP-TEX up-
take by Tsp8+, VEGFR2+ and VEGFR3+ v6kd tumor
cells, TEX particularly colocalizing with Tsp8. TEX were
also taken-up by mouse endothelial cells (EC)
(Additional file 1: Figure S1e). GFP+ non-tumor cells in
BM and lung were mostly and in the liver exclusively
CD11b +mouse monocyte (Mϕ) (Additional file 1: Fig-
ure S1f ). Thus, CIC-TEX uptake is unimpaired in v6kd
and Tsp8kd Non-CIC.
The impact of CIC on distant Non-CIC was evaluated
injecting A818.4-GFP-CIC in the upper left and
A818.4-v6kd cells in the upper right back. A818.4-GFP-CIC
promoted A818.4-v6kd cell growth, differences being first
seen 4wk after tumor cell application (Fig. 1a).
Flow-cytometry revealed very weak green fluorescence in
dispersed v6kd tumor cells that were Tsp8+, EpC+ and
faintly v6+ (Fig. 1b,c). Iv injected CIC-TEX also promoted
A818.4-v6kd and -Tsp8kd cell intrapancreatic growth
resulting in a significant survival time reduction (Fig. 1d), a
strong increase in tumor cell dissemination (peritoneal cav-
ity, PB) and in LN, spleen, BM, liver and lung settlement,
evaluated by tumor cell outgrowth during ex vivo culture,
the cumulated number of organs with disseminated tumor
cells differing significantly (Fig. 1e).
CIC-TEX sufficing to partially rescue metastatic cap-
acity of v6kd and Tsp8kd cells, we searched for the mo-
lecular mechanism(s) underlying CIC-TEX activity.
CIC-TEX affect the CD44v6kd and Tspan8kd non-CIC
mRNA and miRNA profile
The impact of CIC-TEX on kd cells was evaluated by DS
of mRNA and miRNA after 72 h coculture.
A818.4, −v6kd and -Tsp8kd cells contained between
1381 to 1578 mRNA with a signal strength ≥5000. Pan-
ther pathway molecular function analysis revealed a
slightly increased number of structural molecules in the
kd cells (Additional file 1: Figure S2a). A818.4-wt cells
and TEX also displayed similar molecular function pat-
terns (Additional file 1: Figure S2b). Nonetheless,
CIC-TEX significantly affected individual gene expres-
sion in v6kd cells (278 upregulated; 255 downregulated
mRNA) and, less pronounced, Tsp8kd cells (51 upregu-
lated; 63 downregulated mRNA) (≥1000 signal strength,
≥2.0 fold-change) (Additional file 1: Table S3A-S3D and
Figure S2c). Sorting distinctly recovered mRNA in
CIC-TEX-treated v6kd cells according to transcription/
translation, transport, oncogenesis, angiogenesis, apop-
tosis, adhesion/proteolysis and signaling with a focus on
EMT (Reactome database) showed a dominance of up-
or downregulated signaling-engaged mRNA, followed by
RNA engaged in transport and transcription/translation
including splicing. In CIC-TEX-treated Tsp8kd cells
changes in signaling-engaged mRNA also holds the lead-
ing position (Additional file 1: Figure S2d, S2e).
The molecular mechanism of TEX activity being de-
bated, we controlled for a direct mRNA transfer from
CIC-TEX into targets. Only 19 of 51 upregulated mRNA
in Tsp8kd and 60 of 278 upregulated mRNA in v6kd cells
were ≥ 2.0-fold higher in CIC-TEX than untreated kd cells
(Fig. 2a). Similarly, a considerable number of mRNA
≥2.0-fold downregulated after coculture with CIC-TEX
(Tsp8kd: 63 mRNA, v6kd: 255 RNA in cells) were
recovered at an ≥2.0-fold higher level in CIC-TEX than kd
cells, the random correlation between CIC-TEX and
CIC-TEX-treated kd cell mRNA being shown for v6kd
cells (TEX and/or v6kd cell signal strength ≥1000)
(Additional file 1: Table S3E). Additional file 1: Table S3F
presents mRNA of CIC-TEX-treated Tsp8kd cells that ex-
pression was upregulated by CIC-TEX treatment (signal
strength of at least one component ≥1000, fold-change in
untreated versus CIC-TEX-treated Tsp8kd cells: ≥2.0);
mRNA recovery in CIC-TEX is included and ≥ 2.0-fold
higher mRNA recovery in both CIC-TEX and
CIC-TEX-treated Tsp8kd cells is indicated in bold
(Additional file 1: Table S3F). The rare correlation be-
tween recovery in CIC-TEX and CIC-TEX-treated kd cells
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argues against transferred mRNA directly accounting for
changed CIC-TEX-treated kd cell mRNA profiles.
Alternatively, transferred miRNA could account for
mRNA downregulation. The impact of a v6kd or a Tsp8kd
in cells and TEX on miRNA recovery were described (Sun
H. et al., submitted). These studies, performed with miRNA
arrays, cannot be directly compared to the DS analyses.
With the current focus on the impact of CIC-TEX, we just
want to mention that a v6kd more strongly affects miRNA
recovery in cells and TEX than a Tspa8kd, which is shown
for miRNA with a signal strength of > 1000 in TEX, where
a reduction in let7-miRNA in v6kd-TEX is dominating
(Additional file 1: Figure S3a, S3b). The comparison of
miRNA in CIC-TEX versus v6kd or Tsp8kd cells revealed
97 miRNA (signal strength ≥500) showing ≥1.5-fold higher
signal strength in CIC-TEX than the kd cells and an
≥1.5-fold increase in signal strength of 46 miRNA in kd
cells after CIC-TEX treatment (Additional file 1: Table S4A,
S4B and Figure S3c,S3e). Despite qRT-PCR providing evi-
dence for miRNA transfer from CIC-TEX into target cells
(Additional file 1: Figure S3d), an ≥1.5-fold increase in
CIC-TEX-treated kd cells rarely correlated with an ≥1.5
higher recovery in CIC-TEX than kd cells (Fig. 2b). Chan-
ged miRNA recovery poorly reflecting transferred
CIC-TEX miRNA was supported by 30 miRNA downregu-
lation in CIC-TEX-treated v6kd and/or Tsp8kd cells (Add-
itional file 1: Table S4C and Figure S3f). However, within
CIC-TEX-treated kd cells co-culture-induced increased and
reduced miRNA correlated in ≥50% with changed mRNA
expression of predicted targets (http://www.microrna.org,
http://www.targetscan.org) (Additional file 1: Table S5A,
S5B, Fig. 2c). Reactome analysis of predicted mRNA targets
Fig. 1 The impact of CIC-TEX on CD44v6kd and Tspan8kd tumor growth and progression. a-c Nude mice received GFP-transfected A818.4 CIC on
the left upper back and/or A818.4-v6kd cells on the right upper back. a Mean tumor diameter ± SD (3mice/group); b,c mean percent GFP+, GFP
+marker+ and marker+ (v6, Tsp8, EpC) cells was evaluated at autopsy (flow-cytometry); a-c significant differences between mice receiving only
CD44v6kd cells and mice receiving a contralateral injection of CIC-GFP: s. d,e Nude mice received an ot injection of 1 × 106 wt or v6kd or Tsp8kd
cells and weekly 200 μg/mouse CIC-TEX, iv; d survival time and mean survival time of 6 and 5, respectively, mice/group; p-values comparing wt
versus kd tumor and kd tumor depending on CIC-TEX application are indicated. e The indicated organs, collected at autopsy, were dispersed and
maintained in culture to observe tumor cell outgrowth; p-values (Kruskal-Wallis after Bonferroni-Holm correction) for the total No of organs with
disseminated tumor cells are indicated comparing wt versus kd TB mice and CIC-TEX-treated kd TB mice. After reaching a mean tumor diameter
of ~ 0 .5cm, CIC assist the growth of v6kd Non-CIC, likely via delivery of TEX. The shortened survival time and the increase in disseminated tumor
cells of v6kd TB mice receiving CIC-TEX supports this assumption
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of a coculture-promoted ≥2-fold increase or decrease in
both v6kd and Tsp8kd cells and an inverse regulation of
miRNA in v6kd and/or Tsp8kd cells pointed towards tran-
scriptional regulation-engaged mRNA being released from
repression; signaling-engaged mRNA being up- or down-
regulated and metabolism-engaged mRNA frequently being
targets of upregulated miRNA (Fig. 2d).
These findings are hardly compatible with transferred
CIC-TEX mRNA or miRNA directly accounting for
Non-CIC reprogramming, but support CIC-TEX provid-
ing a hub in core signal transducer activation and/or a
shift in the metabolic state. Being concerned about the
crosstalk between CIC-TEX and v6kd or Tsp8kd
Non-CIC, the hypothesis was only surveyed for pro-
nounced changes in signal transduction and selected
features of tumor progression impaired in v6kd and/or
Tsp8kd Non-CIC.
CIC-TEX-promoted signaling, apoptosis-resistance, EMT,
motility and invasion in non-CIC
A signaling array revealed CIC-TEX-promoted activation
of EGFR, Erb2, Erb3, InsR, IGF1R, TrkA1 and -A2, Ron,
RET, EphA1, EphB3, Tyro3, Tie2 and VEGFR2 in v6kd
cells. The impact of CIC-TEX on A818.4-Tsp8kd cells was
partly overlapping. TRKA1, −A2, Tyro3 and TEK did not,
FGFR1, − 3, − 4 and MCSFR became only upregulated in
Tsp8kd cells (Fig. 3a, Additional file 1: Figure S4a and
Table S1). Flow-cytometry and WB confirmed upregulated
EGFR, HER2, EphA1, VEGFR1/2/3 and PDGFRB expres-
sion, where representative examples are presented for the
Fig. 2 Correlation between CIC-TEX and CIC-TEX-induced changes in mRNA and miRNA profiles. a Numbers of ≥2-fold enriched mRNA (signal
strength ≥1000) in CIC-TEX-treated v6kd and Tsp8kd cells sorted according to ≥2-fold higher versus comparable or lower recovery in CIC-TEX
than kd cells; b numbers of miRNA ≥1.5-fold upregulated in CIC-TEX-treated v6kd and Tsp8kd cells sorted according to ≥1.5-fold higher versus
comparable or lower recovery in CIC-TEX than kd cells; c Correlation between ≥1.5-fold up- or downregulated mRNA in CIC-TEX treated v6kd and
Tsp8kd cells sorted according to reverse miRNA recovery in CIC-TEX-treated cells; d major activities (IPA-based Reactome analysis) of ≥2-fold up-
or downregulated mRNA that are predicted targets of inversely recovered miRNA (miRNA database, target scan database) in both CIC-TEX-treated
v6kd and Tsp8kd cell (List of synonyms: Additional file 1: Table S1). mRNA and miRNA recovery are more strongly affected by CIC-TEX treatment
in CD44v6kd than Tsp8kd cells. However, at the mRNA and the miRNA level coculture-induced changes rarely correlate with the CIC-TEX content.
Instead, there is a strong correlation between coculture-induced up- or downregulated miRNA and reversely down- or upregulated mRNA in CIC-
TEX-treated kd cells, indicating that not the CIC-TEX content, but CIC-TEX-induced target cell activation is dominating









Fig. 3 (See legend on next page.)
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WB and relative signal strength compared to the actin
control of 3 independently performed experiments as well
as the p-values of kd cells versus CIC-TEX-treated kd cells
are included (Fig. 3b,c, Additional file 1: Figure S4b and
Table S1). Flow-cytometry analysis indicated src, FAK, ras,
rac, jun and IκB activation by CIC-TEX, although in some
instances v6kd- and Tsp8kd-TEX also exerted weak ef-
fects. WB analysis, representative examples and statistical
evaluation of 3 independently performed WB confirmed
the flow-cytometry results (Fig. 3d,e, Additional file 1: Fig-
ure S4c and Table S1).
Several miRNA ≥2-fold upregulated in CIC-TEX-
treated v6kd and/or Tsp8kd cells target mRNA that are
engaged in RTK signaling and mRNA expression was re-
duced after coculture (Additional file 1: Table S5A).
After coordinating miRNA that was upregulated in v6kd
or Tsp8kd cells after CIC-TEX treatment with predicted
target mRNA that became ≥2-fold downregulated and
searching selectively for an engagement in RTK path-
ways by IPA-based STRING analysis revealed in
CIC-TEX-treated v6kd and Tsp8kd cells Spry (sprouty
RTK signaling antagonists) 4, interfering with multiple
signal transduction molecule activation [37], as the
central target for upregulated miRNA in both
CIC-TEX-treated kd lines (Fig. 3f ). More striking was
the correlation between ≥2-fold reduced miRNA and ≥
2-fold increased predicted mRNA target recovery in the
CIC-TEX-treated kd cells (Additional file 1: Table S5B).
In v6kd and Tsp8kd cells 8 miRNA with ≥2-fold reduced
expression after coculture have four predicted signaling
molecule target mRNA, which became ≥2-fold upregu-
lated after coculture. Only DCBLD2 (discoidin, CUB
and LCCL domain containing 2) and NRP1 (neuropilin1)
are predicted targets of three miRNA. DCBLD2 is a scaf-
fold receptor expression being associated with invasive-
ness [38]. Expression of the CIC marker NRP1 accounts
for higher clonogenicity, self renewal potential and mi-
gratory activity [39]. An additional five miRNA, display-
ing ≥2-fold reduced expression in CIC-TEX-treated
Tsp8kd cells had 8 predicted signaling engaged target
mRNA that expression level became ≥2-fold increased,
the upregulated mRNA being predicted targets of only
one or two downregulated miRNA (Additional file 1:
Figure S4d). Instead, in CIC-TEX-treated v6kd cells add-
itional 29 signal transduction-engaged mRNA with
≥2-fold upregulated expression were predicted targets of
24 miRNA recovered at an ≥2-fold decreased level.
Many of these repression released mRNA were targets
of several miRNA recovered at an ≥2-fold lower level in
CIC-TEX-treated than untreated v6kd cells. The most
prominent likely repression-released target was CDK6
(cyclin-dependent kinase 6), which is not shown as it
predominantly regulates G1 phase progression and G1/S
transition, altered expression being frequently observed
in cancer [40] (Fig. 3g).
In vivo CIC-TEX treatment sufficed for EGFR,
PDGFRB, EphA4, VEGFR2 and NGFR upregulation in
A818.4-v6kd cells and, distinct to the coculture, MAPK
pathway activation (Fig. 3h). Immunohistology confirmed
pronounced VEGFR2/3, PDGFRB, EGFR and EphA4 ex-
pression in v6kd and Tsp8kd tumors of CIC-TEX-treated
mice, PDGFRB becoming particularly upregulated in v6kd
tumors (Fig. 3i). More pronounced activation in tumor tis-
sue than in cocultures could be a sequel of persisting
stimulation and a feedback by the tumor stroma.
Confirming DS analyses, protein and functional in
vitro and in vivo studies suggest RTK and signaling cas-
cade activation relying, at least partly, on CIC-TEX
binding-initiated activation. Upregulation of miRNA that
repress signaling-inhibiting mRNA and miRNA down-
regulation allowing for mRNA release from repression
provide an independent supplemental input, the domin-
ance of v6 probably resting on its engagement in mRNA
and miRNA processing [33]. The strong impact of
CIC-TEX on v6kd cells in modulating miRNA engaged
in RTK and downstream signaling pathways activation
demands putting emphasis on unequivocally answering
the mode of action.
(See figure on previous page.)
Fig. 3 CIC-TEX-initiated changes in RTK and downstream signaling molecules in CD44v6kd and Tspan8kd cells. a Signaling array of A818.4-v6kd
cells cultured for 72 h with/without CIC-TEX. The relative signal strength was evaluated by ImageJ; significant differences by coculture with CIC-
TEX: *. Flow-cytometry and WB analysis of (b,c) RTK expression in kd-TEX- or CIC-TEX-treated kd cells and (d,e) major pathway-engaged cytosolic
signaling molecules; b,d mean % stained cells±SD (3 assays), significant differences by coculture with TEX: *; c,e representative examples and
relative signal strength±SD of 3 independent experiments including p-values for kd cells compared to CIC-TEX-treated kd cells; f pathways from
miRNA to RTK (IPA-based STRING analysis after predicted target mRNA selection by microrna.org and targetscan.org) for ≥2-fold upregulated
miRNA (framed) and ≥ 2-fold reduced mRNA recovery in CIC-TEX-treated v6kd or Tsp8kd cells compared to untreated kd cells; g IPA-based
STRING analysis after predicted target mRNA selection by microrna.org and targetscan.org for ≥2-fold reduced miRNA in CIC-TEX-treated
compared to untreated v6kd cells and of ≥2-fold upregulated predicted mRNA targets that are engaged in signal transduction. h Flow-cytometry
analysis of ex vivo harvested intrapancreatic A818.4-v6kd cells from nude mice with/without weekly iv CIC-TEX treatment; mean % stained cells
±SD (3 tumors), significant differences by CIC-TEX treatment: s; i Representative immunohistology examples of A818.4-v6kd and -Tsp8kd shock-
frozen tumor sections with/without CIC-TEX treatment stained with the indicated antibodies (scale bar: 100 μm). (List of synonyms: Additional file
1: Table S1). CIC-TEX treatment strongly affects RTK expression and downstream signaling molecules in vitro and in vivo. Changes in the recovery
of mRNA engaged in signal transduction (Additional file 1: Figure S2d, S2e) are accompanied at a noteworthy frequency by reversely altered
miRNA expression in CIC-TEX-treated kd, predominantly v6kd cells
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Apoptosis-resistance being a central CIC feature, we
proceeded searching for the impact of transferred
CIC-TEX on apoptosis resistance of v6kd and Tsp8kd
cells cultured for 48 h in the presence of cisplatin. Re-
duced apoptosis resistance of v6kd and Tsp8kd cells being
partially corrected by CIC-TEX coculture (Fig. 4a), hints
towards the underlying molecular processes were searched
for by DS, controlling for selected proteins in vitro and ex
vivo by flow-cytometry and immunohistochemistry.
Sorting by Reactome analysis in v6kd and Tspan8kd cells
for apoptosis-related mRNA that expression was ≥2-fold al-
tered after coculture with CIC-TEX according to the en-
gagement in regulation of apoptosis, receptor-mediated or
intrinsic apoptosis pathways revealed a predominant contri-
bution of mRNA engaged in apoptosis regulation. Notably,
Hyal2 (hyaluronoglucosaminidase 2) [41, 42] became
down- and Dicer [43] upregulated in CIC-TEX-treated
v6kd cells. Hardly any contribution of mRNA engaged in
receptor-mediated apoptosis was seen and only few mRNA
involved in the intrinsic apoptosis pathway were affected.
Most notably was the upregulation of ABC (ATP binding
cassette) drug transporters that was only observed in v6kd
cell cocultures with CIC-TEX (Fig. 4b). Predicted targets of
miRNA engaged in apoptosis/apoptosis regulation were
searched by the microrna.org and targetscan.org program.
Though ≥2-fold up- or downregulated miRNA and mRNA
frequently inversely correlated, only few predicted mRNA
were targets of at least 3 miRNA. These included the down-
regulated mRNA CDKN1A/p21 (cyclin dependent kinase
inhibitor 1A) [44], CLU (clusterin) [45], DHCR24 (24-de-
hydrocholesterol reductase) [46], SFN (stratifin) [47],
STAT1 [48], TGM2 (transglutaminase 2) [49] and VEGFB
[50], mostly engaged in apoptosis regulation and rarely in
intrinsic apoptotic signaling. NGFR (nerve growth factor re-
ceptor) also is engaged in death receptor signaling [51].
Only upregulated EMP1 (epithelial membrane protein 1)
and PMAIP1 (phorbol-12-myristate-13-acetate-induced
protein 1), engaged in regulation of the intrinsic apoptosis
pathway and apoptosis execution [52, 53], are predicted tar-
gets of several downregulated miRNA. Thus, none of the
potential miRNA targets plays a central role in apop-
tosis. Notably, drug transporter mRNA was not a pre-
dicted target of any miRNA showing altered
expression in CIC-TEX-treated v6kd and Tsp8kd cells
(Additional file 1: Figure S5a, S5b).
A Tsp8kd having a minor impact, CIC-TEX correction
of apoptosis-resistance at the protein level is only shown
for v6kd cells exhibiting slightly upregulated actCasp3
and cleaved Casp9 and reduced MDR1, pAkt and pBAD
expression (Fig. 4c,d). CIC-TEX treatment uncovered
pAkt, Bcl2, BclXl upregulation and a minor BAX reduc-
tion, dominating being MDR1 upregulation (Fig. 4e,f ).
The impact of CIC-TEX on apoptosis-related genes be-
came stronger in vivo. Immunohistochemistry of v6kd
tumor sections revealed upregulated Casp3 and Casp9
being reduced and reduced TNFRI, AIF and MDR1 ex-
pression being rescued in CIC-TEX-treated v6kd-TB
mice (Fig. 4g).
CIC-TEX hardly affected receptor-mediated apoptosis
and apoptosis-executing molecules, but rescued ABC
transporter expression in v6kd cells. A minor contribution
of CIC-TEX to PI3K/Akt pathway activation likely
accounts for v6kd and Tsp8kd cells. CIC-TEX-promoted
changes in miRNA have a mean impact on apoptosis-re-
sistance, predicted mRNA frequently are potential targets
of only one or two miRNA. The stronger effects of
CIC-TEX treatment in vivo point towards additive sup-
port by the tumor surrounding. Nonetheless, the less im-
pressive changes by CIC-TEX treatment of v6kd and
Tsp8kd cells fit to the weak impact of CIC-TEX on apop-
tosis resistance.
CIC-TEX can promote EMT, which beside others sup-
ports anchorage-independent growth, evaluated by col-
ony formation in soft agar. Anchorage-independent
growth of v6kd and Tsp8kd cell was strongly reduced
compared to wt cells, but was rescued in cultures con-
taining CIC-TEX, but not v6kd- or Tsp8kd-TEX
(Fig. 5a). CIC also are characterized by slow cell cycle
progression, which was evaluated after synchronization
(48 h starving) by PI uptake. Cell cycle progression was
accelerated in v6kd and Tsp8kd cells compared to CIC
and became significantly retarded in CIC-TEX-treated
kd cells (Fig. 5b).
DS analysis of EMT marker and EMT-related tran-
scription factor expression indicated low signal strength
(< 500) for most EMT markers and EMT-regulating
transcription factors. Nonetheless, NOTCH1, TWIST1,
LPR6 and SOX4 were ≥ 1.5-fold upregulated in
CIC-TEX-treated v6kd cells (data not shown). However,
IPA-based Reactome analysis uncovered a significant
number of transcription factors and transcription regu-
lating mRNA as well as of mRNA engaged in Wnt and,
less frequently NOTCH, BMP and SCF-Kit signaling
that expression was ≥2-fold changed, predominantly in
v6kd cells after CIC-TEX coculture. Notably, expression
of 6 mRNA, explicitly engaged in EMT regulation, was
reduced in CIC-TEX-treated v6kd cells. Expression of
only few mRNA was ≥2-fold up- or downregulated in
both v6kd and Tsp8kd cells or in Tsp8kd cells after
CIC-TEX treatment. EMT-related activities of these lat-
ter mRNA corresponded to those described for
CIC-TEX-treated v6kd cells (Fig. 5c).
There is additional evidence for a possible contribu-
tion of miRNA to EMT regulation. Eight, respectively,
seven miRNA with ≥2-fold increased recovery in
CIC-TEX-treated v6kd and Tsp8kd cells concomitantly
displayed ≥2-fold downregulation of EMT-related pre-
dicted target mRNA. The bHLH MYCL (MYC lung







Fig. 4 CIC-TEX-promoted apoptosis-resistance in CD44v6kd and/or Tspan8kd cells. a Flow-cytometry of cells cultured for 48 h in the presence of
cisplatin; mean % AnnexinV+ and AnnexinV+/PI+ cells±SD (triplicates); significant differences of wt cells versus CIC or kd cells: *; significant
differences by CIC-TEX treatment: s. b mRNA that expression differed by ≥2-fold after CIC-TEX treatment in Tsp8kd (blue) or v6kd (violet) cells
were sorted by KEGG analysis according to the engagement in distinct apoptotic processes. c-f Flow-cytometry analysis of apoptosis-related
receptor and cytoplasmic signaling molecules in A818.4, −v6kd and CIC-enriched cells and in v6kd cells cocultured with v6kd- or CIC-TEX; mean
% stained cells±SD (3 assays), significant differences between wt cells, v6kd cells and CIC: *, significant differences by coculture of v6kd cells with
TEX: s. g Representative immunohistology examples of A818.4 and -v6kd shock-frozen tumor sections from untreated or CIC-TEX-treated mice
stained with the indicated antibodies (scale bar: 100 μm). (List of synonyms: Additional file 1: Table S1). Slightly reduced apoptosis resistance of
v6kd and Tsp8kd tumor cells becomes mitigated by CIC-TEX treatment. The impact of CIC-TEX on apoptosis resistance is mostly restricted to the
regulation of molecules engaged in the intrinsic pathway of apoptosis induction. An exception is the increased expression of drug transporters in
CIC-TEX-treated v6kd cells
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carcinoma derived homolog) transcription factor [54]
appears to be central in modulating EMT in v6kd cells
in response to CIC-TEX-promoted miRNA upregulation.
In Tspan8kd cells the transglutaminase TGM2, promot-
ing apoptosis resistance and tumor progression [55], is a
predicted target by several CIC-TEX-promoted upregu-
lated miRNA (Fig. 5d). On the other hand, a higher
number of miRNA that have predicted mRNA targets
engaged in the EMT process were expressed at an
≥2-fold reduced level after CIC-TEX coculture, where
CDK6, CSNK1A1 (casein kinase 1 alpha 1) and PPP3CA
(protein phosphatase 3 catalytic subunit alpha) are pre-
dicted targets of several miRNA. CDK6 is primarily en-
gaged in cell cycle regulation [56], the impact on EMT
remaining to be further explored. However, STRING
analysis revealed that 10 of 15 mRNA possibly released
from miRNA repression in the v6kd and/or Tsp8kd cells,
including CSNK1A1 [57] and PPP3CA [58] are engaged
in Wnt and 4 in NOTCH signaling (Fig. 5e).
Protein analysis confirmed unaltered E-cadherin and
vimentin expression in the v6kd and Tsp8kd Non-CIC










b Fig. 5 The impact of CIC-TEX on EMT gene expression. a Tumor
cells were seeded in soft agar containing 30 μg/ml TEX, where
indicated; mean No of colonies±SD (5 replicates) and representative
examples after 3wk of culture; b cell cycle progression (flow-
cytometry, PI staining) of wt, CIC and kd cells cultured with/without
CIC-TEX; mean % of cells (5 replicates) in G0, G1/S and G2/M; c IPA-
based Reactome analysis of transcription factor-, stem cell-, EMT-,
transcription-, and EMT-regulating genes that mRNA level is ≥2-fold
up- or downregulated in CIC-TEX-treated v6kd and Tsp8kd cells
(red), Tsp8kd cells (blue) or CD44v6kd cells (violet). d,e Reactome
analysis after IPA coordination of miRNA with predicted mRNA
targets (miRNA and targetscan databases) of (d) > 2-fold
upregulated miRNA (framed) and (e) downregulated miRNA in CIC-
TEX-treated kd cells affecting EMT-related genes in kd cells; in (d)
mRNA pathways from upregulated miRNA towards EMT are
included; for downregulated miRNA (e) only direct predicted mRNA
targets are shown (color code as in c). f Flow-cytometry of EMT
markers in A818.4 and kd cells with/without CIC-TEX-treatment (72
h); g confocal microscopy of kd cells with/without CIC-TEX-
treatment stained for E- or N-cadherin and counterstained for v6 or
Tsp8 (scale bar: 10 μm); h Flow-cytometry of ex vivo analyzed EMT
markers in dispersed intrapancreatic v6kd tumors from mice with/
without CIC-TEX-treatment; (i) Flow-cytometry of EMT-related
transcription factors in A818.4 and kd cells with/without CIC-TEX-
treatment (72 h); j Confocal microscopy of kd cells with/without CIC-
TEX-treatment stained for EMT-related transcription factors NOTCH
and Nanog and counterstained with anti-v6 or anti-Tsp8 (scale bar:
10 μm); f,h,i mean % stained cells±SD (3 assays/tumors); a,b,f,h,i
significant differences between wt and kd cells: *, significant
differences by CIC-TEX-treatment: s. (List of synonyms: Additional file
1: Table S1). CIC-TEX partly rescue impaired anchorage-independent
growth and accelerate kd cell cycle progression. DS, confirmed at
the protein level, unraveled a strong impact of CIC-TEX on EMT-
related transcription factors mostly in v6kd cells at the mRNA and
miRNA level, the latter being particularly engaged in Wnt and
NOTCH signaling
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reduced N-cadherin expression in v6kd and Tsp8kd cells
and reduced fibronectin (FN) expression in Tsp8kd cells
(Fig. 5f). Confocal microscopy endorsed unaltered
E-cadherin expression in the CIC-TEX-treated kd cells
and pronounced colocalization with v6; CIC-TEX-pro-
moted upregulated N-cadherin also preferentially coloca-
lized with v6 (Fig. 5g). Upregulated N-cadherin, but
unaltered E-cadherin, FN and vimentin expression was
also seen in ex vivo analyzed dispersed v6kd tumor tissue
from CIC-TEX-treated mice (Fig. 5h). Protein analysis
confirmed CIC-TEX coculture mostly rescuing reduced
NOTCH and Nanog expression in v6kd and Tsp8kd cells
and Slug, Snail, Twist and Wnt5a/b expression in v6kd
cells (Fig. 5i), confocal microscopy affirming for NOTCH
and Nanog colocalization with v6 and Tsp8 (Fig. 5j).
CD44v6 and Tspan8 contribute to tumor cell motility
and invasion and defects of v6kd and Tspan8kd cells are
corrected by CIC-TEX. The contribution of Tspan8 relies
on its association with integrins, driving beside others
α6β4 out of hemidesmosomes into TEM, where integrins
become activated promoting cytosolic signaling molecule
activation that allows for lamellipodia and focal adhesion
point generation. Tspan8 also is engaged in protease acti-
vation mostly via associated membrane-anchored MMP
[25, 34]. CD44v6 promotes activation of protease tran-
scription and protease proform cleavage, which facilitates
generating space for migrating tumor cells [32, 59]. These
findings being already demonstrated for A818.4-v6kd and
-Tspan8kd cells as well as the partial correction of deficits
by CIC-TEX [32, 34], the question on the correlation with
the DS analysis remained to be answered.
We evaluated at the mRNA level proteases and adhesion
molecules that were upregulated after coculture of v6kd or
Tspan8kd cells with CIC-TEX by ≥1.5-fold. Excluding the
proteasome, comparably few proteases were distinctly re-
covered with a surprisingly high percentage of protease in-
hibitors. This accounted for CIC-TEX-treated v6kd and
Tsp8kd cells. Adhesion molecule analysis, restricted to
membrane-anchored and cytoskeleton interacting proteins
(ligands indicated in brackets) revealed CIC-TEX treatment
fostering integrin, laminin, cadherin- and actin-interacting
protein expression (Fig. 6a). STRING pathway analysis of
adhesion molecule RNA with upregulated expression after
CIC-TEX treatment uncovered predominant upregulation
of integrin-, GPCR- and RTK-signaling pathway compo-
nents, indicated in brackets, in v6kd cells (Fig. 6b).
DS confirmed the engagement of Tsp8 and v6 in adhe-
sion/migration and kd cell deficit correction by
CIC-TEX and unraveled an abundance of upregulated
cadherin-binding mRNA and of protease inhibitors.
Attacking CIC-TEX
Taking the strong CIC-TEX impact on Non-CIC tumor
progression, CIC-TEX blocking could provide a mean
improving adjuvant PaCa therapy. TEX-Tsp8 most effi-
ciently binding targets [28], CIC-TEX were blocked by
an anti-Tsp8 antibody (CO029), not captured by xeno-
geneic host cells. CIC-TEX-promoted signal transduc-
tion activation was attacked by GEM, a standard drug in
adjuvant PaCa treatment [60].
Nude mice received a sc A818.4-v6kd cell injection
and 2-times/wk. CIC-TEX, iv. Where indicated, mice
were weekly treated with GEM or CO029. The survival
time of CIC-TEX-treated mice was significantly reduced.
GEM and CO029 sufficed coping with the impact of
CIC-TEX (Fig. 7a). CIC-TEX-promoted tumor cell dis-
semination in PB, LN and lung was mitigated in
GEM-treated mice. CO029 additionally affected settle-
ment in the BM (Fig. 7b).
To mimic the clinical situation, mice received sc A818.4
cells and weekly GEM or CO029, iv. GEM retarded tumor
growth early after application, CO029 became efficient
after 4-5wk, GEM and CO029 significantly delaying tumor
growth (Fig. 7c). More impressive was the interference
with tumor cell dissemination. Settlement in draining LN
was prevented in 2, recovery in the PB in 3 of 6 mice. Par-
ticularly CO029 potently coped with settlement in BM
and lung. Tumor cell dissemination in GEM or
CO029-treated mice, evaluated in ex vivo cultures, was
significantly reduced (Fig. 7d).
Stem cell marker, angiogenesis-, apoptosis-, proteolysis-
and adhesion-related molecule expression was evaluated
6wk after A818.4 application by flow-cytometry and at aut-
opsy by immunohistochemistry. CO029 affected Tsp8 and
associated CD104 expression in the primary tumor and the
BM (Fig. 7e), reduced expression being also seen at autopsy.
An impact of GEM on expression of the CIC-markers v6,
Tsp8, CD104 and CD184 in tumor tissue became apparent
only by immunohistochemistry performed with shock-
frozen tumor tissue at autopsy (Fig. 7f). Only CO029 af-
fected VEGFR3 expression in tumor cells and BMC (Fig.
7g). At autopsy angiogenesis was reduced in tumors of
GEM- and CO029-treated mice; CO029 sufficed for miti-
gating lymphangiogenesis (reduced VEGFR3 expression),
which might explain the stronger impact of Tsp8 on meta-
static settlement (Fig. 7h). Only GEM application was ac-
companied by an increase in apoptotic cells (AnnV+ and PI
+) and prominently increased TIMP1 expression. Immuno-
histochemistry at autopsy revealed a slight MMP2 reduc-
tion in GEM- and CO029-treated mice that was not seen
in flow-cytometry, while TIMP1 upregulation by GEM was
confirmed (Fig. 7i,j). Both GEM and CO029 promoted a
minor reduction of some integrins and CD56. Tumor cell
dissemination-facilitating myeloid-derived suppressor cells
(MDSC) were strongly reduced in the BM of GEM-treated
mice (Fig. 7k,l).
Briefly, GEM and CO029 counterbalance several
CIC-TEX-initiated tumor progression-promoting effects,
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CO029 most efficiently interfering with tumor cell dis-
semination, whereas GEM drives apoptosis and affects
hematopoiesis. Promising for combining anti-Tsp8 treat-
ment with chemotherapy, the therapeutic effects of
GEM and CO029 are independent.
Discussion
CIC-TEX promote tumor progression affecting host cells
and Non-CIC [4, 8, 61], the mode of CIC-TEX modulat-
ing targets and an active CIC marker contribution being
debated. DS of CIC-TEX, human v6kd and Tsp8kd PaCa
Non-CIC and v6kd and Tsp8kd Non-CIC cocultured
with CIC-TEX and functional in vitro and in vivo con-
trols enlightened the contribution of v6 and Tsp8 to a
range of CIC activities as well as to central aspects of
CIC-TEX operation, particularly CIC-TEX content likely
promoting a switch in the activation state of central sig-
naling components. The model and our conclusions will
be discussed.
CD44v6kd and Tsp8kd non-CIC and CIC-TEX uptake
CD44v6kd and Tspan8kd PaCa lines can be considered as
Non-CIC due to the loss in metastatic capacity [32–34].
This finding on the one hand strengthens v6 and Tsp8 be-
ing CIC-biomarkers and on the other hand allowed unrav-
eling their contribution(s) to the metastatic process.
Overlapping activities of two apparently independent CIC
markers are due to the association in invagination prone
TEM, Tsp8 playing a prominent role in TEX biogenesis
and targeting and v6 in vesicle loading [26, 28, 33, 62].
Joint loss of activities is endorsed by v6 regulating Tsp8
transcription [32]. Furthermore, CIC-TEX and kd cells
originating from one parental clone facilitates coordinat-
ing molecular and functional changes, strengthening the
suitability of these CIC-marker kd models evaluating
CIC-TEX activities of v6 and Tsp8.
CIC-TEX uptake by v6kd and Tsp8kd cells is unim-
paired. Uptake in the xenogeneic system by EC and
monocytes, to be interpreted with caution, nonetheless re-
inforces the CIC-TEX - host crosstalk [61, 62]. CIC-GFP
supporting at a distant site injected v6kd Non-CIC growth
after 4wk and weak GFP expression at autopsy in ~ 10%
of v6kd Non-CIC pointed towards released GFP-TEX
activity, affirmed by increased recovery of dissemi-
nated v6kd and Tsp8kd Non-CIC in CIC-TEX-treated
mice. Thus, v6kd and Tsp8kd cells take-up function-
relevant CIC-TEX.
Deep sequencing as a tool elaborating the mode of
CIC-TEX activity
CIC-TEX target modulation could be due to the liber-
ated TEX content or, not mutually exclusive, CIC-TEX
Fig. 6 CIC-TEX engagment in protease, adhesion molecule and related signaling regulation in CD44v6kd and Tspan8kd cells. a CIC-TEX coculture-
induced ≥1.5-fold upregulated RNA expression was analyzed by KEGG for engagement in proteolysis and adhesion. The analysis was restricted to
plasma membrane or plasma membrane attached proteins; proteases and inhibitors (indicated in brackets) are listed for migration; for adhesion
molecules the predominant ligands are included in brackets. b Assignment of major adhesion / motility promoting signaling molecules (STRING
analysis) that expression was ≥1.5-fold upregulated by CIC-TEX coculture; major targets are indicated in brackets. (Abbreviations: AJ: adherens
junction, cadh: cadherin, chemok: chemokine, coll: collagen, CS: chondroitin sulphate, cytosk: cytoskeleton, FN: fibronectin, GPCR: G-protein
coupled receptor, growthF: growth factors, HA: hyaluronan, inhib: inhibitor, int: integrin, LN: laminin, Synd: syndecan, List of synonyms: Additional
file 1: Table S1). CIC-TEX affect proteases and more frequently adhesion molecules in v6kd and Tsp8kd cells. CIC-TEX often promote protease
inhibitor upregulation. Besides matrix binding molecules, the linkage to the actin cytoskeleton and binding to cadherin is dominating. Altered
adhesion molecule-promoted signaling frequently proceeds directly via activated integrins, RTK and GPCR










Fig. 7 (See legend on next page.)
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binding-promoted target cell activation or the TEX con-
tent acting as a hub [14, 61]. The latter suggestions are
supported by the small Exo plasma hosting limited
amounts of proteins, RNA and DNA and by Exo derived
from cell clones distinctly affecting different targets [62].
DS was performed with CIC-TEX, untreated and
CIC-TEX-treated v6kd and Tsp8kd cells. Due to the co-
culture components relatedness, CIC-TEX uptake pro-
voked a limited number of coculture-initiated altered
mRNA and miRNA recoveries in v6kd and Tsp8kd
Non-CIC. DS of Capan1 sphere-derived CIC-TEX,
Capan1-v6kd cells and CIC-TEX-treated Capan1-v6kd
cells revealed concordant results in > 90% (signal
strength cutoff: ≥1000), data not shown for clarity of
presentation.
Functional assignment of distinctly recovered mRNA
in CIC-TEX-treated v6kd and Tsp8kd cells showed dom-
inant engagement in signaling, transport, transcription
and translation. However, neither increased nor de-
creased mRNA correlated with recovery in CIC-TEX.
Thus, changed recovery after coculture does not reflect
the TEX content, which also accounts for changed
miRNA recovery. Instead, recovery of predicted targets
of distinctly recovered cellular miRNA inversely corre-
lated in ≥50%. miRNA-repressed or -released mRNA
were mainly engaged in metabolism, signaling and tran-
scription, assignments based on few miRNA-mRNA
pairs may not essentially be representative, yet fit to dis-
tinctly recovered mRNA in CIC-TEX-treated v6kd and
Tsp8kd Non-CIC. One also should take the possibility
into account that the activity of TEX miRNA on cellular
mRNA translation is missed by the evaluation of mRNA.
As after 48 h–72 h coculture the cellular miRNA and the
predicted mRNA level inversely correlated in > 50%, we
suggest that the coculture period sufficed for covering the
impact of miRNA on mRNA translation. Nonetheless, this
option should be further explored. Finally, long noncoding
(lnc)RNA needs mentioning discussing mRNA release
from repression. Abundant lncRNA frequently act as
miRNA sponges [63], but current knowledge does not
allow a systemic integration into miRNA interfering with
mRNA translation.
DS uncovered CIC-TEX more strongly affecting
mRNA and miRNA in v6kd than Tsp8kd Non-CIC,
which is due to v6 engagement in RTK and transcription
factor activation, alternative splicing and miRNA pro-
cessing [16, 33, 43, 64, 65]. This finding is not opposing
a Tsp8kd and a v6kd similarly affecting tumor progres-
sion [25, 65, 66], the impact of a Tsp8kd being due to
tetraspanin engagement in TEX-biogenesis and -bind-
ing/uptake [28, 32, 34].
DS analysis pointing towards CIC-TEX binding-initi-
ated target cell activation and CIC-TEX content transfer
acting as a hub was confirmed in vitro and in vivo for
selected, tumor progression-associated processes at the
protein level.
CIC-TEX-promoted v6kd and Tsp8kd non-CIC activation,
apoptosis-resistance, EMT, motility and tumor
progression
Protein analysis of CIC-TEX-treated v6kd and Tsp8kd
Non-CIC uncovered RTK upregulation including in
v6kd cells Met and EphA4, both interacting with and ac-
tivated by v6 binding [67, 68]. Occasional cytoplasmic
signaling molecule activation after coculture with
kd-TEX obviates an exclusive CIC-TEX contribution.
Nonetheless, confirming in vitro studies, v6kd tumor ex
vivo analysis from CIC-TEX-treated mice additionally
uncovered MAPK pathway activation [69], missed after
in vitro coculture.
Pathway analysis of upregulated miRNA targets in
CIC-TEX-treated v6kd and Tsp8kd Non-CIC backed
some miRNA engagement in CIC-TEX-initiated signal-
ing, the main target being Spry4, inhibiting beside others
the MAPK pathway [37, 70]. More abundant were up-
regulated mRNA, correlating with reduced miRNA re-
covery. Notably, the majority of predicted mRNA being
targets of more than one miRNA, like CDK6, DCBLD2,
(See figure on previous page.)
Fig. 7 Binding and RTK inhibition for blocking CIC-TEX activity as adjuvant PaCa therapy. Mice received an ot (A818.4-v6kd) or a sc (A818.4)
tumor cell injection and weekly the RTK inhibitor GEM (iv) or anti-Tsp8 (CO029) (iv). a Survival time and mean survival time of v6kd-TB mice
(intrapancreatic) treated with CIC-TEX (2x/wk) and GEM or CO029 (1x/wk). b Recovery of disseminated tumor cells in cultures of dispersed organs
at autopsy. c Tumor growth rate, survival time and mean survival time of sc A818.4-TB mice, treated with GEM or CO029; d disseminated tumor
cell recovery in cultures of dispersed organs at autopsy; a-d p-values for the mean survival time and the numbers of organs containing dispersed
tumor cells (after Bonferroni-Holm correction) of GEM- or CO029-treated compared to untreated v6kd-TB and CIC-TEX-treated-TB or wt-TB are
indicated. e,g,i,k,l Flow-cytometry of dispersed tumor cells and BMC of untreated and GEM- or CO029-treated A818.4-TB mice evaluating CIC,
angiogenic, apoptosis, proteolysis, adhesion (only tumor cells) marker expression and MDSC (CD11b + Gr1+) (only BMC); mean % stained cells±SD
(3 mice), significant differences by GEM- or CO029-treatment: *. f,h,j Immunohistology of A818.4 shock-frozen tumor sections from untreated,
GEM- or CO029-treated mice stained for CIC markers, VEGFR2, VEGFR3, CD31, MMP2 and TIMP1 (scale bar: 100 μm). GEM and CO029 weakly affect
tumor growth and strongly tumor cell dissemination. Ex vivo analysis indicates that GEM and CO029 act independently. GEM primarily affects
tumor cell apoptosis, proteases and MDSC expansion, CO029 treatment is accompanied by a reduction in (Tsp8-associated) CIC markers and
compromises (lymph)angiogenesis
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GOLT1B (Golgi transport 1B), GTF2F2 (general tran-
scription factor IIF subunit 2), HES7 (hes family bHLH
transcription factor 7), MBP (myelin basic protein),
PMAIP1 and PPP3CA, are engaged in cancer-related
signaling pathways (reviewed in [71]).
Briefly, CIC-TEX initiate v6kd and Tsp8kd Non-CIC
modulation by suppressing or activating signaling pathways
and by launching miRNA processing or silencing with con-
comitant mRNA repression/release of repression. This
powerful networking underscores CIC-TEX-promoted
modulation of signaling in v6kd and Tsp8kd Non-CIC as
hub for regaining CIC-features.
CIC-TEX, hardly affecting components of receptor-me-
diated apoptosis or the mTOR/Pten pathway, promoted
upregulation of ID1 (inhibitor of DNA binding 1, HLH
protein), PIM1 and PIM3 (Proto-oncogene, serine/threo-
nine kinase-1, − 3), negative regulators of apoptosis [54,
72–74]. However, DS revealed significant upregulation of
4 drug transporters in CIC-TEX-treated v6kd cells and
CIC-TEX-promoted MDR1 expression was miRNA-inde-
pendent. CD44 plays a central role in ABC regulation [75]
and stem cell Exo / CIC-TEX confer drug resistance [76].
At least in the context of v6kd Non-CIC, TEX-promoted
ABC upregulation is the dominating mechanism in trans-
ferring apoptosis resistance. A weak coculture-induced ef-
fect on apoptosis resistance of Tspan8kd cell may rely on
PI3K/Akt pathway activation.
There were few possibly miRNA-related changes in
apoptosis resistance. We already mentioned that the
most prominent targets, like p21, DHCR24, Clu, NGFR,
SFN, STAT1, PMAIP1, EMP1, VEGFB and TGM, the
only mRNA selectively affected in Tspan8kd cells [55],
have multiple functions [44–53], one of the activities of
the heat shock protein-similar chaperone Clusterin being
apoptosis inhibition by interfering with Bax activation
and cytochrome C release [45], BAX expression being
slightly reduced in CIC-TEX-treated v6kd cells. Also,
EMP1, reported to be downregulated in cancer, can up-
regulate Casp9 [52]. However, none of these possibly
miRNA-regulated mRNA were engaged in receptor pro-
moted apoptosis.
Thus, a major contribution of CIC-TEX to strengthen
v6kd apoptosis-resistance relies on ABC transporter up-
regulation. A minor input by PI3K/Akt pathway compo-
nents, displaying pronounced phosphorylation, will be
missed by DS analyses.
EMT or partial EMT induction is a central feature of
CIC [77, 78] and involves CIC-marker expression [79]
including CD44 [80]. The confirmation for CD44v6,
Tspan8 [4, 31, 32] and CD133 strengthening their defin-
ition as CIC-biomarkers. From the classical EMT
markers, only N-cadherin [81] was affected by the v6kd
and the Tsp8kd, reduced expression becoming corrected
in vitro and in vivo by CIC-TEX. Notably, an
unexpectedly high number of up- or downregulated
mRNA after CIC-TEX coculture is engaged in transcrip-
tion, translation, Wnt, Nanog or Notch signaling, some of
these mRNA being also targets of CIC-TEX
coculture-affected miRNA, downregulated miRNA mostly
repressing Wnt and NOTCH signaling-engaged mRNA.
At the protein level, CIC-TEX induced a partial NOTCH,
Nanog and Twist rescue, showing pronounced v6 and
Tsp8 colocalization. Flow-cytometry indicated a Slug,
Snail, Twist and Wnt5a/b rescue in CIC-TEX-treated
v6kd cells. The findings, in line with EMT-related tran-
scription factors assisting tumor progression [78],
reinforce the v6 contribution to Wnt, NOTCH and Nanog
activation and to miRNA processing [17, 18, 21, 22, 82].
These CIC-TEX activities could rely on the abundant re-
covery of E2F transcription factor, histone proteins and
RISC components in CIC-TEX [83, 84]. Whether the
transferred proteins act autonomously or as hub, awaits
clarification. All required components being available in
Non-CIC and Exo-induced EMT being restricted to em-
bryonic development and tumor cells [85], an initiating
CIC-TEX trigger may be dominating.
Controlling by DS the CIC-TEX contribution to mi-
gration promoting activity (Fig. 6) [25, 32], two obser-
vations, missed at the protein level, need mentioning.
A comparably high number of protease inhibitors be-
came upregulated by CIC-TEX treatment. Increased
laminin, collagen and FN matrix protein expression in
CIC-TEX-treated v6kd and Tsp8kd Non-CIC suggests
a feedback loop to guarantee sufficient extracellular
matrix (EMC) organization for guiding migrating
tumor cells. Furthermore, a high number of mRNA
engaged in cadherin-promoted adhesion became up-
regulated by CIC-TEX treatment. E-cadherin expres-
sion, though not consistently observed, is supposed to
become reduced during EMT [81]. Occupying
E-cadherin by different ligands, preventing homophilic
adhesion, could fulfill a similar task as downregula-
tion. Taking into account membrane integrated and
actin binding components, DS confirmed the contri-
bution of CIC-TEX in promoting a motile phenotype
of v6kd and Tsp8kd Non-CIC, integrins, their ECM
ligands and cytoskeleton reorganization being import-
ant players.
Blocking CIC-TEX mitigates the impact on targets
Drug combinations improved adjuvant chemotherapy ef-
ficacy in PaCa, success still being unsatisfactory [37].
CIC-TEX contributing to poor PaCa prognosis, we and
others explored a CIC-TEX-uptake blockade of the
major PaCIC-TEX targeting molecule Tsp8 [28–30]. In
view of the impressive activation of RTK by CIC-TEX
the kinase inhibitor GEM [60] was used as an alternative
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option. We confirmed complementation of these two
adjuvant therapies. Both GEM and CO029 slightly pro-
longed the survival time and strongly impaired tumor
cell dissemination. Only CO029 affected Tsp8-associated
CIC biomarker expression and reduced tumor cell re-
covery in the BM. GEM predominantly supported
apoptosis-susceptibility, protease expression and in the
BM a shift towards MDSC. Angiogenesis-related recep-
tor expression was affected by both, lymphangiogenesis
receptor expression predominantly in CO029-treated
mice.
The supplementing activities of GEM and CO029,
antibody application not being burdened by severe side
effects, might considerably improve PaCa adjuvant
therapy.
Conclusions
CIC-TEX strongly influence v6kd and Tsp8kd Non-CIC,
predominantly affecting signaling, transcription, transla-
tion, but also miRNA processing with a feedback on
mRNA translation. The v6 CIC marker, engaged in all
these processes, takes the lead. Unraveling CIC-TEX
binding/transfer likely acting as hub will have profound
bearing on understanding the crosstalk between exo-
somes and targets and be most helpful envisaging out-
smarting CIC-TEX, a blockade of CIC-TEX uptake via
anti-Tsp8 offering an independent, additive adjuvant
therapeutic (Fig. 8).
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